Lerisetron. FAES.
作者信息
Huckle Richard
机构信息
Axovan Ltd, Gewerbestrasse 16, 4123 Ailschwil, Switzerland.
出版信息
Curr Opin Investig Drugs. 2003 Jul;4(7):874-7.
PMID:14619411
Abstract
Lerisetron is a 5-hydroxytryptamine3 receptor antagonist under development by FAES Farma for the potential treatment of emesis resulting from chemotherapy. Phase I trials of lerisetron were underway in Spain by 1994, and as of June 2000, the compound was in phase II trials in the UK. By the end of 2001, phase II trials had been completed and phase III trials had commenced.
摘要
Zotero 插件